The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Addition of low‐dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients
Abstract
Summary: Aims This study was designed to test the efficacy and safety of low‐dose rosiglitazone, a potent, insulin‐sensitizing thiazolidinedione, in combination with sulphonylurea in Type 2 diabetic patients. Methods For the intention‐to‐treat analysis, 574 patients (59% male, mean age 61 years) were available, randomized to receive 26 weeks of twice‐daily placebo (n = 192), rosiglitazone 1 mg (n = 199) or rosiglitazone 2 mg (n = 183) in addition to existing sulphonylurea treatment with gliclazide (47.6% of patients), glibenclamide (41.8%) or glipizide (9.4%) (two patients were taking carbutamide or glimepiride). Change in haemoglobin A 1c (HbA 1c), fasting plasma glucose (FPG), fructosamine, insulin, C‐peptide, albumin, and lipids were measured, and safety was evaluated. Results Mean baseline HbA 1c was 9.2% and FPG was 11.4 mmol/l. Rosiglitazone at doses of 1 and 2 mg b.d. plus sulphonylurea produced significant decreases, compared with sulphonylurea plus placebo, in HbA 1c (−0.59% and −1.03%, respectively; both P < 0.0001) and FPG (1.35 mmol/l and 2.44 mmol/l, respectively; both P < 0.0001). Both HDL‐cholesterol and LDL‐cholesterol increased and potentially beneficial decreases in non‐esterified fatty acids and gamma glutamyl transpeptidase levels were seen in both rosiglitazone groups. The overall incidence of adverse experiences was similar in all three treatment groups, with no significant cardiac events, hypoglycaemia or hepatotoxicity. Conclusions Overall, the combination of rosiglitazone and a sulphonylurea was safe, well tolerated and effective in patients with Type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance.
National Diabetes Data Group (1979) · Diabetes · doi:10.2337/diab.28.12.1039 · Cited by 4,909
Pathogenesis of NIDDM. A balanced overview.
DeFronzo, R. A., Bonadonna, R. C., & Ferrannini, E. (1992) · Diabetes Care · doi:10.2337/diacare.15.3.318 · Cited by 2,085
Low-Density Lipoprotein Subclass Patterns and Risk of Myocardial Infarction
Austin, M. A. (1988) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1988.03410130125037 · Cited by 1,780
Thiazolidinediones in the Treatment of Insulin Resistance and Type II Diabetes
Saltiel, A. R., & Olefsky, J. M. (1996) · Diabetes · doi:10.2337/diab.45.12.1661 · Cited by 1,053
Role of Insulin Resistance in Human Disease (Syndrome X): An Expanded Definition
Reaven, G. M. (1993) · Annual Review of Medicine · doi:10.1146/annurev.me.44.020193.001005 · Cited by 912
Cholesterol and Coronary Heart Disease: Predicting Risks by Levels and Ratios
Kinosian, B., Glick, H., & Garland, G. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-121-9-199411010-00002 · Cited by 519
Thiazolidinediones: a new class of antidiabetic drugs
Day, C. (1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00023.x · Cited by 436
Groop, L. C. (1992) · Diabetes Care · doi:10.2337/diacare.15.6.737 · Cited by 408
Prospective Study of Serum γ-Glutamyltransferase and Risk of NIDDM
Perry, I. J., Wannamethee, S. G., & Shaper, A. G. (1998) · Diabetes Care · doi:10.2337/diacare.21.5.732 · Cited by 319
Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk
Krauss, R. M. (1994) · Current Opinion in Lipidology · doi:10.1097/00041433-199410000-00005 · Cited by 230
Piaggesi, A., Schipani, E., Campi, F., Romanelli, M., Baccetti, F., Arvia, C., & Navalesi, R. (1998) · Diabetic Medicine · doi:10.1002/(sici)1096-9136(199805)15:5<360::aid-dia568>3.0.co;2-w · Cited by 182
Patel, J., Anderson, R. J., & Rappaport, E. B. (1999) · Diabetes, Obesity and Metabolism · doi:10.1046/j.1463-1326.1999.00020.x · Cited by 181
Austin, M. A., Mykkänen, L., Kuusisto, J., Edwards, K. L., Nelson, C., Haffner, S. M., Pyörälä, K., & Laakso, M. (1995) · Circulation · doi:10.1161/01.cir.92.7.1770 · Cited by 164
Horton, E. S., Whitehouse, F. W., Ghazzi, M. N., Venable, T. C., The Troglitazone Study Group, & Whitcomb, R. W. (1998) · Diabetes Care · doi:10.2337/diacare.21.9.1462 · Cited by 138
The Effect of Leptin Is Enhanced by Microinjection Into the Ventromedial Hypothalamus
Jacob, R. J., Dziura, J. D., Medwick, M. B., Leone, P., Caprio, S., During, M. J., Shulman, G. I., & Sherwin, R. (1997) · Diabetes · doi:10.2337/diab.46.1.150 · Cited by 134
Fagot‐Campagna, A., Balkau, B., Simon, D., Warnet, J. M., Claude, J. R., Ducimetière, P., & Eschwège, E. (1998) · International Journal of Epidemiology · doi:10.1093/ije/27.5.808 · Cited by 134
A Novel Antidiabetic Drug, Troglitazone — Reason for Hope and Concern
Imura, H. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381311 · Cited by 57
Section Review: Oncologic, Endocrine & Metabolic: Thiazolidinediones
Whitcomb, R. W., & Saltiel, A. R. (1995) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.4.12.1299 · Cited by 43
Allauzen, S., Mani, J. C., Granier, C., Pau, B., & Bouanani, M. (1995) · Journal of Immunological Methods · doi:10.1016/0022-1759(95)00020-b · Cited by 33
Buysschaert, M., Bobbioni, E., Starkie, M., Frith, L., & For The Troglitazone Study Group (1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00029.x · Cited by 32
Hosokawa, Y., & Leahy, J. L. (1997) · Diabetes · doi:10.2337/diab.46.5.808 · Cited by 32
Allauzen, S. (1995) · Molecular Immunology · doi:10.1016/0161-5890(94)00133-l · Cited by 29
Cardiovascular disease and hyperlipidaemia
Krauss, R. M., & niemi, Y. A. K. (1994) · Current Opinion in Lipidology · doi:10.1097/00041433-199408000-00001 · Cited by 24
Cited by
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Chinetti, G., Lestavel, S., Bocher, V., Remaley, A. T., Neve, B., Torra, I. P., Teissier, E., Minnich, A., Jaye, M., Duverger, N., et al. (2001) · Nature Medicine · doi:10.1038/83348 · Cited by 1,170
“In addition, glitazone PPAR-α activators induce HDL-cholesterol, but not apoAI levels, by an unknown mechanis”
BackgroundOral Antihyperglycemic Therapy for Type 2 Diabetes: Scientific Review
Inzucchi, S. E. (2002) · JAMA · doi:10.1001/jama.287.3.360 · Cited by 1,065
Lipids and Lipoproteins in Patients With Type 2 Diabetes
Krauss, R. M. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1496 · Cited by 756
β-Cell Failure in Diabetes and Preservation by Clinical Treatment
Wajchenberg, B. L. (2007) · Endocrine Reviews · doi:10.1210/10.1210/er.2006-0038 · Cited by 714
Metadata
- Authors
- Wolffenbuttel, B. H. R., Gomis, R., Squatrito, S., Jones, N. P., & Patwardhan, R. N.
- Venue
- Diabetic Medicine
- Publisher
- Wiley
- Published
- 2000-01
- Volume
- 17
- Issue
- 1
- Pages
- 40-47
- ISSN
- 0742-3071 (ISSN-L)
- 1464-5491
- OpenAlex
- W2169421904
- Cited by
- 264
- References
- 26
- FWCI
- 24.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.